Practices affEcting macitentan and selexipag patient persistence Rates utilizing pulmonary arterial hypertension clinical Site and patIent perSpecTives (PERSIST): a US qualitative analysis

Oksana A. Shlobin; Gary Bruce; Gabriela Gomez-Rendon; Martha Kingman; Mohammad Rahman; Frances Rogers; Sean Studer; Tobore Tobore; Colleen McEvoy

doi:10.1002/pul2.12441

Practices affEcting macitentan and selexipag patient persistence Rates utilizing pulmonary arterial hypertension clinical Site and patIent perSpecTives (PERSIST): a US qualitative analysis

Oksana A. Shlobin
, Gary Bruce
, Gabriela Gomez-Rendon
, Martha Kingman
, Mohammad Rahman
, Frances Rogers
, Sean Studer
, Tobore Tobore
, Colleen McEvoy

Research output: Contribution to journal › Letter › peer-review

5 Scopus citations

Abstract

This real-world study explored factors affecting persistence with macitentan and selexipag treatment from the perspective of 23 healthcare professionals (HCPs) and 134 patients with pulmonary arterial hypertension between 2019 and 2022. Continuous patient/HCP communication and education were key drivers of persistence, as were early discussion and management of side effects.

Original language	English
Article number	e12441
Journal	Pulmonary Circulation
Volume	14
Issue number	4
DOIs	https://doi.org/10.1002/pul2.12441
State	Published - Oct 2024

Keywords

healthcare professional discussion tool
patient perspectives
pulmonary hypertension

Access to Document

10.1002/pul2.12441

Cite this

Shlobin, O. A., Bruce, G., Gomez-Rendon, G., Kingman, M., Rahman, M., Rogers, F., Studer, S., Tobore, T., & McEvoy, C. (2024). Practices affEcting macitentan and selexipag patient persistence Rates utilizing pulmonary arterial hypertension clinical Site and patIent perSpecTives (PERSIST): a US qualitative analysis. Pulmonary Circulation, 14(4), Article e12441. https://doi.org/10.1002/pul2.12441

@article{8c5bf76d771a4e88b067facdf5a5e9db,

title = "Practices affEcting macitentan and selexipag patient persistence Rates utilizing pulmonary arterial hypertension clinical Site and patIent perSpecTives (PERSIST): a US qualitative analysis",

abstract = "This real-world study explored factors affecting persistence with macitentan and selexipag treatment from the perspective of 23 healthcare professionals (HCPs) and 134 patients with pulmonary arterial hypertension between 2019 and 2022. Continuous patient/HCP communication and education were key drivers of persistence, as were early discussion and management of side effects.",

keywords = "healthcare professional discussion tool, patient perspectives, pulmonary hypertension",

author = "Shlobin, \{Oksana A.\} and Gary Bruce and Gabriela Gomez-Rendon and Martha Kingman and Mohammad Rahman and Frances Rogers and Sean Studer and Tobore Tobore and Colleen McEvoy",

note = "Publisher Copyright: {\textcopyright} 2024 Actelion Pharmaceuticals US, Inc. Pulmonary Circulation published by John Wiley \& Sons Ltd on behalf of Pulmonary Vascular Research Institute.",

year = "2024",

month = oct,

doi = "10.1002/pul2.12441",

language = "English",

volume = "14",

journal = "Pulmonary Circulation",

issn = "2045-8932",

number = "4",

}

Shlobin, OA, Bruce, G, Gomez-Rendon, G, Kingman, M, Rahman, M, Rogers, F, Studer, S, Tobore, T & McEvoy, C 2024, 'Practices affEcting macitentan and selexipag patient persistence Rates utilizing pulmonary arterial hypertension clinical Site and patIent perSpecTives (PERSIST): a US qualitative analysis', Pulmonary Circulation, vol. 14, no. 4, e12441. https://doi.org/10.1002/pul2.12441

Practices affEcting macitentan and selexipag patient persistence Rates utilizing pulmonary arterial hypertension clinical Site and patIent perSpecTives (PERSIST): a US qualitative analysis. / Shlobin, Oksana A.; Bruce, Gary; Gomez-Rendon, Gabriela et al.
In: Pulmonary Circulation, Vol. 14, No. 4, e12441, 10.2024.

Research output: Contribution to journal › Letter › peer-review

TY - JOUR

T1 - Practices affEcting macitentan and selexipag patient persistence Rates utilizing pulmonary arterial hypertension clinical Site and patIent perSpecTives (PERSIST)

T2 - a US qualitative analysis

AU - Shlobin, Oksana A.

AU - Bruce, Gary

AU - Gomez-Rendon, Gabriela

AU - Kingman, Martha

AU - Rahman, Mohammad

AU - Rogers, Frances

AU - Studer, Sean

AU - Tobore, Tobore

AU - McEvoy, Colleen

PY - 2024/10

Y1 - 2024/10

N2 - This real-world study explored factors affecting persistence with macitentan and selexipag treatment from the perspective of 23 healthcare professionals (HCPs) and 134 patients with pulmonary arterial hypertension between 2019 and 2022. Continuous patient/HCP communication and education were key drivers of persistence, as were early discussion and management of side effects.

AB - This real-world study explored factors affecting persistence with macitentan and selexipag treatment from the perspective of 23 healthcare professionals (HCPs) and 134 patients with pulmonary arterial hypertension between 2019 and 2022. Continuous patient/HCP communication and education were key drivers of persistence, as were early discussion and management of side effects.

KW - healthcare professional discussion tool

KW - patient perspectives

KW - pulmonary hypertension

UR - https://www.scopus.com/pages/publications/85206246270

U2 - 10.1002/pul2.12441

DO - 10.1002/pul2.12441

M3 - Letter

C2 - 39398324

AN - SCOPUS:85206246270

SN - 2045-8932

VL - 14

JO - Pulmonary Circulation

JF - Pulmonary Circulation

IS - 4

M1 - e12441

ER -

Practices affEcting macitentan and selexipag patient persistence Rates utilizing pulmonary arterial hypertension clinical Site and patIent perSpecTives (PERSIST): a US qualitative analysis

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this